GS
Therapeutic Areas
Tharimmune Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TH104 (buccal nalmefene film) | Chronic pruritus in Primary Biliary Cholangitis (PBC) | Phase 2 |
| TH104 | Pruritus associated with Atopic Dermatitis | Preclinical |
Leadership Team at Tharimmune
RM
Randy Milby
Founder, Chief Executive Officer, Chairman of the Board
BC
Brendan Cavanagh
Chief Operating Officer and Interim Chief Financial Officer
DK
Dr. Kumaraguruparan (Kumar) Subramanian
Chief Scientific Officer
DJ
Dr. James A. Rothman
Independent Director
DM
Dr. Michael G. Gray
Independent Director